11C-MC1

DRUG3 trials

Sponsors

National Institute of Mental Health (NIMH)

Conditions

ALSAlzheimer's DiseaseDementiaHealthy VolunteersInflammatoryMild Cognitive ImpairmentMultiple SclerosisMyositis

Phase 1

Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions

TerminatedNCT03912428

National Institute of Mental Health (NIMH)Healthy Volunteers, Inflammatory, Myositis +1

Start: 2019-06-14End: 2024-06-14Updated: 2025-09-16

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

RecruitingNCT04396873

National Institute of Mental Health (NIMH)ALS, Alzheimer's Disease, Dementia +2

Start: 2021-08-17End: 2030-10-03Target: 184Updated: 2026-02-17

Phase 2

PET Imaging of Cyclooxygenase in Multiple Sclerosis

TerminatedNCT05062083

National Institute of Mental Health (NIMH)Multiple Sclerosis

Start: 2022-06-07End: 2024-01-30Updated: 2024-06-27

Related Papers

PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study.

2020-05-0245 citations